You have free access to this content

Cancer

Cover image for Cancer

15 October 2006

Volume 107, Issue 8

Pages 1711–1929

  1. Commentary

    1. Top of page
    2. Commentary
    3. Review Article
    4. Original Articles
    1. You have free access to this content
      Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations (pages 1711–1742)

      Holly L. Howe, Xiaocheng Wu, Lynn A. G. Ries, Vilma Cokkinides, Faruque Ahmed, Ahmedin Jemal, Barry Miller, Melanie Williams, Elizabeth Ward, Phyllis A. Wingo, Amelie Ramirez and Brenda K. Edwards

      Version of Record online: 6 SEP 2006 | DOI: 10.1002/cncr.22193

      This collaborative annual report provides an update to cancer incidence and death rates and trends in the United States through 2003. It also includes a special section on cancer among U.S. Latino/Hispanic populations.

  2. Review Article

    1. Top of page
    2. Commentary
    3. Review Article
    4. Original Articles
    1. You have free access to this content
      Antibiotic prophylaxis in neutropenic patients : New evidence, practical decisions (pages 1743–1751)

      Leonard Leibovici, Mical Paul, Michael Cullen, Giampaolo Bucaneve, Anat Gafter-Gvili, Abigail Fraser and Winfried V. Kern

      Version of Record online: 14 SEP 2006 | DOI: 10.1002/cncr.22205

      • original image
      • original image
      • original image
      • original image
      • original image

      The authors report that prophylaxis with ciprofloxacin or levofloxacin should be considered in patients who are treated for acute leukemia or who receive high-dose chemotherapy with stem cell transplantation. Prophylaxis to cover the expected period of neutropenia may be considered for the first cycle of treatment in patients with solid tumors or lymphoma. High prevalence of resistance to fluoroquinolones should prompt a reconsideration of this policy.

  3. Original Articles

    1. Top of page
    2. Commentary
    3. Review Article
    4. Original Articles
    1. Disease Site

      Breast Disease
      You have free access to this content
      Health profiles of younger and older breast cancer survivors (pages 1752–1759)

      Charles J. Stava, Adriana Lopez and Rena Vassilopoulou-Sellin

      Version of Record online: 11 SEP 2006 | DOI: 10.1002/cncr.22200

      • original image
      • original image

      Physiologic and psychosocial differences distinguish younger breast cancer survivors from older breast cancer survivors. In this study, the results suggested that a systematic analysis of cancer survivors is needed to understand their unique health profiles and needs.

    2. You have free access to this content
      Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ (pages 1760–1768)

      Lei Huo, Nour Sneige, Kelly K. Hunt, Constance T. Albarracin, Adriana Lopez and Erika Resetkova

      Version of Record online: 14 SEP 2006 | DOI: 10.1002/cncr.22216

      • original image

      In a group of 200 patients who were diagnosed with ductal carcinoma in situ of the breast on core-needle biopsy, the presence of a mass, lesion size >1.5 cm, and the presence of lobular cancerization on core-needle biopsy were independent predictors of invasion on surgical excision. A multivariate logistic regression model was developed to predict invasion. One hundred three patients underwent sentinel lymph node biopsy, and 3 patients had a single lymph node metastasis.

    3. You have free access to this content
      Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening (pages 1769–1776)

      Kent F. Hoskins, Alice Zwaagstra and Michael Ranz

      Version of Record online: 11 SEP 2006 | DOI: 10.1002/cncr.22202

      • original image

      A pedigree assessment tool (PAT) designed to identify women in population-based screening at risk for hereditary breast cancer syndromes was developed. The PAT performed better than the Gail model at identifying women in a screening mammography population who are appropriate candidates to refer for genetic counseling and DNA testing for BRCA gene mutations.

    4. You have free access to this content
      Recreational physical activity and survival among young women with breast cancer (pages 1777–1785)

      Page E. Abrahamson, Marilie D. Gammon, Mary Jo Lund, Julie A. Britton, Stephen W. Marshall, Elaine W. Flagg, Peggy L. Porter, Louise A. Brinton, J. William Eley and Ralph J. Coates

      Version of Record online: 11 SEP 2006 | DOI: 10.1002/cncr.22201

      • original image

      The authors investigated whether recreational physical activity undertaken prior to diagnosis influenced breast cancer survival among a population-based cohort of 1264 young women. Some evidence was observed for a beneficial effect on survival of activity undertaken in the year prior to diagnosis, particularly among women who were overweight or obese near the time of diagnosis.

    5. Endocrine Disease
      You have free access to this content
      Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens (pages 1786–1792)

      Yongjin Wang, Richard Tsang, Sylvia Asa, Brendan Dickson, Tamara Arenovich and James Brierley

      Version of Record online: 11 SEP 2006 | DOI: 10.1002/cncr.22203

      • original image
      • original image

      External beam radiotherapy can result in local control of anaplastic thyroid carcinoma. A twice-daily fractionation regimen is well tolerated and has a trend to longer survival.

    6. Genitourinary Disease
      You have free access to this content
      Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma (pages 1793–1800)

      Revathi Suppiah, Philip E. Shaheen, Paul Elson, Seema A. Misbah, Laura Wood, Robert J. Motzer, Slyvie Negrier, Steven W. Andresen and Ronald M. Bukowski

      Version of Record online: 18 SEP 2006 | DOI: 10.1002/cncr.22237

      • original image

      Thrombocytosis is prevalent in various malignancies, including metastatic renal cell carcinoma. A platelet count >400,000/μL is an independent prognostic factor for survival in patients with metastatic renal cell carcinoma.

    7. Gynecologic Oncology
      You have free access to this content
      Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer (pages 1801–1811)

      Josep Castellvi, Angel Garcia, Federico Rojo, Carmen Ruiz-Marcellan, Antonio Gil, Jose Baselga and Santiago Ramon y Cajal

      Version of Record online: 18 SEP 2006 | DOI: 10.1002/cncr.22195

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The objective of this study was to identify molecules and other factors that clearly reflect the oncogenic role of a specific pathway in ovarian cancer. The results indicated that 4E binding protein 1 (4EBP1) is a possible hallmark of cell signaling that may act as a pivotal factor in oncogenic pathways and that phosphorylated 4EBP1 (p-4EBP1) expression, which is detectable with immunohistochemistry, is associated with tumor progression and an adverse prognosis. The authors suggest studying p-4EBP1 as a new molecular marker in ovarian tumors, regardless of the status of other possible oncogenic alterations.

    8. You have free access to this content
      The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module : EORTC QLQ-CX24 (pages 1812–1822)

      Elfriede R. Greimel, Karin Kuljanic Vlasic, Ann-Charlotte Waldenstrom, Vlatka M. Duric, Pernille T. Jensen, Susanne Singer, Weichu Chie, Andy Nordin, Vesna Bjelic Radisic, Dariusz Wydra and on behalf of the European Organization for Research and Treatment of Cancer Quality-of-Life Group

      Version of Record online: 14 SEP 2006 | DOI: 10.1002/cncr.22217

      The authors report on the development and validation of a cervical cancer module for the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life (QoL) Questionnaire (EORTC QLQ-CX24). The results of this study indicated that the EORTC QLQ-CX24 is a valid and reliable instrument to assess QoL in patients who are treated for cervical cancer. The QLQ-CX24 supplements the 30-item core EORTC QLQ (QLQ-C30) to evaluate disease-specific and treatment-specific aspects of QoL in clinical trials.

    9. You have free access to this content
      Therapeutic role of lymph node resection in endometrioid corpus cancer : A study of 12,333 patients (pages 1823–1830)

      John K. Chan, Michael K. Cheung, Warner K. Huh, Kathryn Osann, Amreen Husain, Nelson N. Teng and Daniel S. Kapp

      Version of Record online: 14 SEP 2006 | DOI: 10.1002/cncr.22185

      • original image

      The findings of the current study suggest that the extent of lymph node resection improves the survival of women with intermediate/high-risk endometrioid uterine cancer.

    10. Head and Neck Disease
      You have free access to this content
      Analysis of differential BRAFV600E mutational status in multifocal papillary thyroid carcinoma : Evidence of independent clonal origin in distinct tumor foci (pages 1831–1838)

      So Yeon Park, Young Joo Park, Yu Jin Lee, Hyun Sook Lee, Sung Hee Choi, Gheeyoung Choe, Hak-Chul Jang, Seong Hoe Park, Do Joon Park and Bo Youn Cho

      Version of Record online: 18 SEP 2006 | DOI: 10.1002/cncr.22218

      • original image
      • original image

      At least 39.3% of multifocal papillary cancers in the Korean population could be attributed to independently originating papillary cancers rather than to intrathyroidal spread of single cancers.

    11. Hematologic Malignancies
      You have free access to this content
      Treatment of acute myelogenous leukemia with outpatient azacitidine (pages 1839–1843)

      Nimit Sudan, James M. Rossetti, Richard K. Shadduck, Joan Latsko, John A. Lech, Robert B. Kaplan, Margaret Kennedy, Jeffrey F. Gryn, Yacoub Faroun and John Lister

      Version of Record online: 11 SEP 2006 | DOI: 10.1002/cncr.22204

      • original image
      • original image

      Azacitidine administered in the outpatient setting can induce remission in acute myeloid leukemia (AML). The therapy is well tolerated and might be an alternative for patients unlikely to tolerate standard induction chemotherapy.

    12. You have free access to this content
      Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas (pages 1844–1851)

      Nalan Akyurek, Yongsheng Ren, Georgios Z. Rassidakis, Ellen J. Schlette and L. Jeffrey Medeiros

      Version of Record online: 18 SEP 2006 | DOI: 10.1002/cncr.22219

      • original image
      • original image
      • original image

      Differential expression of inhibitor of apoptosis proteins (IAPs) in B-cell lymphomas suggest differences in pathogenesis that might have implications for novel treatment strategies targeting IAPs.

    13. Hepatobiliary Disease
      You have free access to this content
      Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis (pages 1852–1858)

      Oscar Arrieta, Jose Luis Rodriguez-Diaz, Vanessa Rosas-Camargo, Daniela Morales-Espinosa, Sergio Ponce de Leon, David Kershenobich and Eucario Leon-Rodriguez

      Version of Record online: 11 SEP 2006 | DOI: 10.1002/cncr.22198

      • original image

      The current study evaluated the effect of colchicine on the development of hepatocellular carcinoma (HCC). The results suggest that colchicine may prevent and delay the development of HCC in patients with hepatitis virus-related cirrhosis.

    14. Lung Disease
      You have free access to this content
      Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion (pages 1859–1865)

      Susana Benlloch, Jose Marcelo Galbis-Caravajal, Concepcion Martín, Jose Sanchez-Paya, Jose Manuel Rodríguez-Paniagua, Santiago Romero, Juan Jose Mafe and Bartomeu Massutí

      Version of Record online: 18 SEP 2006 | DOI: 10.1002/cncr.22190

      • original image

      The authors investigated the diagnostic value of methylation profiles for discrimination between malignant and benign pleural effusions and examined the concordance of methylation in samples of serum and pleural fluid. The results indicated that adequate management of extracted pleural fluid can provide a rapid and reliable diagnosis in patients with pleural effusions who have suspected malignancy.

    15. You have free access to this content
      Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer (pages 1866–1872)

      Yoshihiko Segawa, Katsuyuki Hotta, Shigeki Umemura, Yoshiro Fujiwara, Tetsu Shinkai, Hiroshi Ueoka, Nagio Takigawa, Masahiro Tabata, Katsuyuki Kiura and Mitsune Tanimoto

      Version of Record online: 11 SEP 2006 | DOI: 10.1002/cncr.22207

      • original image
      • original image

      In the current series of previously treated Japanese patients with advanced nonsmall cell lung cancer who had benefited from gefitinib treatment for at least 6 months, baseline brain metastasis was strongly associated with the emergence of acquired resistance to gefitinib.

    16. You have free access to this content
      Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer (pages 1873–1882)

      Chih-Hsin Yang, Jin-Yuan Shih, Kun-Chieh Chen, Chong-Jen Yu, Tsung-Ying Yang, Ching-Pei Lin, Wen-Pin Su, Chien-Hung Gow, Chiun Hsu, Gee-Chen Chang and Pan-Chyr Yang

      Version of Record online: 20 SEP 2006 | DOI: 10.1002/cncr.22220

      • original image

      The response rate to gefitinib in 120 chemonaive East Asian patients with advanced nonsmall cell lung cancer who had a good performance status was 52%. The median survival of 11.1 months and the 1-year survival rate of 47.5% were similar to those achieved by patients who received chemotherapy as initial treatment. Female gender, adenocarcinoma histology, and nonsmoking status were independent predictors of a response to gefitinib.

    17. Melanoma
      You have free access to this content
      Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain : High rate of thromboembolic events (CALGB 500102) (pages 1883–1890)

      Susan E. Krown, Donna Niedzwiecki, Wen-Jen Hwu, Lydia Hodgson, Alan N. Houghton, Frank G. Haluska and for the Cancer and Leukemia Group B

      Version of Record online: 19 SEP 2006 | DOI: 10.1002/cncr.22239

      • original image
      • original image

      Of 16 patients with melanoma brain metastases treated with the combination of extended-dose temozolomide and thalidomide, none showed an antitumor response, 4 developed thromboembolic events, and 1 died suddenly. The high proportion of patients with life-threatening or lethal adverse events in the absence of objective tumor responses provide little support for the use of this combination unless safe and effective methods to prevent thrombosis are developed.

    18. Neuro-Oncology
      You have free access to this content
      Prognostic stratification of patients with anaplastic gliomas according to genetic profile (pages 1891–1897)

      Caroline Dehais, Florence Laigle-Donadey, Yannick Marie, Michele Kujas, Julie Lejeune, Alexandra Benouaich-Amiel, Marta Pedretti, Marc Polivka, Khe-Hoang Xuan, Joelle Thillet, Jean-Yves Delattre and Marc Sanson

      Version of Record online: 19 SEP 2006 | DOI: 10.1002/cncr.22211

      • original image
      • original image

      An unsupervised recursive partitioning analysis, which included clinical, histologic, and genetic markers, was applied to a series of 156 anaplastic gliomas and led to a simple prognostic subclassification, with 1p19q codeletion and epidermal growth factor receptor amplification as the most discriminating prognostic factors.

    19. Sarcoma
      You have free access to this content
      Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor (pages 1898–1908)

      Jonathan C. Trent, Latha Ramdas, Jheri Dupart, Kelly Hunt, Homer Macapinlac, Ellen Taylor, Limei Hu, August Salvado, James L. Abbruzzese, Raphael Pollock, Robert S. Benjamin and Wei Zhang

      Version of Record online: 19 SEP 2006 | DOI: 10.1002/cncr.22214

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Gastrointestinal stromal tumor cells and human tumor samples sensitive to imatinib up-regulate the expression of insulin-like growth factor binding protein-3 after imatinib exposure.

    20. Discipline

      Symptom Control and Palliative Care
      You have free access to this content
      Quality-of-life and health benefits of early treatment of mild anemia : A randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies (pages 1909–1917)

      David J. Straus, Marcia A. Testa, Brenda J. Sarokhan, Myron S. Czuczman, Anil Tulpule, Ralph R. Turner and Shirley A. Riggs

      Version of Record online: 14 SEP 2006 | DOI: 10.1002/cncr.22221

      • original image
      • original image
      • original image

      A randomized, open-label, multicenter trial demonstrated that early treatment of mild anemia (hemoglobin ≥10 g/dL to ≤12 g/dL) with epoetin alfa, but not delayed intervention (when hemoglobin <9 g/dL), significantly improves quality of life, productivity, and hemoglobin level during chemotherapy for hematologic malignancies. The findings support the early use of epoetin alfa for mild anemia inpatients undergoing chemotherapy for hematologic malignancy, a population known to have a high prevalence of chemotherapy-related anemia.

    21. Translational Research
      You have free access to this content
      The role of Src in solid and hematologic malignancies : Development of new-generation Src inhibitors (pages 1918–1929)

      Ricardo H. Alvarez, Hagop M. Kantarjian and Jorge E. Cortes

      Version of Record online: 19 SEP 2006 | DOI: 10.1002/cncr.22215

      • original image
      • original image
      • original image
      • original image

      c-Src was the first oncogene described in humans, and its functions are related to signal transduction and to the development of metastatic potential in solid and hematologic tumors. In this review, the authors describe the new concepts of c-Src in the process of transformation of solid and hematologic malignancies. In addition, the authors describe the new generation of Src inhibitors and their potential application in oncology.

SEARCH

SEARCH BY CITATION